Intracellular infectious agents stimulate several thousand antigen-specific naive CD8^+^ T cells to expand up to 10,000-fold resulting in lymphocytosis and lymphadenopathy ([@bib60]). Within this expanded T cell population, there exist several distinct subsets that can be characterized by both function and phenotype. Cells exhibiting strong cytotoxicity to the instigating agent express high levels of perforin, granzymes, and the killer cell lectin--like receptor G1 (KLRG1). With sterilizing immunity, many of these terminally differentiated effector cells die at a high rate over a 2-wk period after the peak of the expansion. In contrast, a subset of T cells does not express KLRG1, displays a relatively reduced rate of cell death, and preferentially contributes to indelible antigen-specific immune memory ([@bib52]; [@bib41]). Experiments with single-cell transfers show that these diverse populations arise from a common precursor ([@bib54]; [@bib14]), and this commitment may be influenced early in the process of naive T cell activation ([@bib9]; [@bib8]).

The differentiation and expansion of CD8^+^ effector T cells depends on co-stimulation, growth factors such as IL-2 ([@bib59]; [@bib4]; [@bib37]; [@bib46]), and inflammatory cytokines, especially IL-12, that promote the expression of TBX21 ([@bib11]; [@bib56]; [@bib24]; [@bib43]). Further studies have shown that IL-2 acts, in part, through the transcriptional repressor BLIMP1 (encoded by *Prdm1*); accordingly, *Prdm1*^−/−^ T cells display a defect in effector cell differentiation and more readily form memory-precursor cells. The pro-memory transcriptional profile that includes *Bcl6*, *Tcf7*, and *Eomes* is inhibited by BLIMP1, whereas a transcription factor associated with effector T cells, TBX21, is enhanced by BLIMP1 ([@bib28]; [@bib50]; [@bib53]; [@bib23]; [@bib61]).

Studies have shown that the AKT signaling pathway promotes effector cell differentiation at the expense of memory cell precursors ([@bib17]; [@bib31]). In addition, the mammalian target of rapamycin, a downstream target of AKT, is a major regulator of memory CD8^+^ T cell differentiation ([@bib3]; [@bib44]). Thus treatment with rapamycin or metformin enhanced both the quantity and quality of memory CD8^+^ T cells. Because inhibition of the FOXO1 transcription factor is a major conduit of AKT-mediated signaling, we set out to determine whether FOXO1 broadly affects the contingency of effector versus memory-precursor differentiation, and to what extent FOXO1 determines the program of memory T cell gene expression. Here, we show that the loss of *Foxo1* has little effect on the expansion and survival of antigen-stimulated CD8^+^ T cells, but causes them to maintain an activated effector phenotype. These persisting *Foxo1*-null T cells were unable to expand upon reactivation, and this phenotype correlated with a extensive pattern of gene expression that favors the formation of effector T cells. We conclude that FOXO1 regulates the fate of effector versus memory-precursor T cells, and this has implications for the manner with which the physiological state of the organism impacts the outcome of an immune response.

RESULTS
=======

Normal expansion of Foxo1^−/−^ CD8^+^ T cells after viral infection
-------------------------------------------------------------------

To study the role of FOXO1 in CD8^+^ T cells responding to a viral infection in vivo, we took advantage of mice in which exon 2 of *Foxo1* is flanked by *loxP* sites (*Foxo1*^f/f^ mice; [@bib40]). Because crossing *Foxo1*^f/f^ mice with mice carrying the Tg(Cd4-cre)1Cwi transgene (Cd4Cre mice) results in autoimmunity caused by a defect on regulatory T cells ([@bib30]), we produced *Foxo1*^f/f^ mice with the Cre recombinase under the control of the human Granzyme B promoter (GZMBCre). Recombination was thus restricted to activated CD8^+^ T cells ([@bib22]; [@bib50]). These mice were further crossed to include the P14 T cell antigen receptor transgenes (P14) endowing T cells with specificity for the immunodominant epitope of lymphocytic choriomeningitis virus (LCMV) gp33 in association with H2D^b^. Equal numbers of spleen cells from *Foxo1*^f/f^GZMBCre^+^P14^+^ (*Foxo1*^−/−^ P14) and *Foxo1*^f/f^GZMBCre^−^P14^+^ (WT P14) mice were co-transferred into naive host mice, and the T cells were followed by expression of CD45.2 or CD45.1/2, respectively. Recipient mice were then infected with LCMV Armstrong (LCMV-Arm; [@bib38]). The analysis of splenic T cells revealed an equivalent expansion of *Foxo1*^−/−^ and WT P14 T cells upon viral infection with little or no difference in the rate of contraction ([Fig. 1 A](#fig1){ref-type="fig"}). Although there appears to be a slight delay in the contraction of *Foxo1*^−/−^ T cells in the experiment presented, this was not consistently seen in three other independent experiments. In addition, similar percentages of Ki-67^+^ cells in WT and *Foxo1*^−/−^ P14 cells were found at the peak of the response (7 d after infection) with virtually no Ki-67^+^ cells present at days 12 and 19 ([Fig. 1 B](#fig1){ref-type="fig"}, top panels and bottom graph). Since FOXO1 is important for the expression of the homing molecules, [l]{.smallcaps}-selectin (CD62L) and CCR7 ([@bib13]; [@bib29]), we examined CD62L expression in the spleen and the distribution of WT and *Foxo1*^−/−^ P14 cells after viral infection in lymph nodes (LN), lungs, and liver. As expected, expression of CD62L was low on *Foxo1*^−/−^ P14 cells compared with WT P14 cells ([Fig. 1 C](#fig1){ref-type="fig"}). However, *Foxo1*^−/−^ T cells were at least as abundant as WT P14 T cells in all the organs analyzed, excluding a defect in the homing capacity of *Foxo1*^−/−^ P14 cells due to low CD62L expression ([Fig. 1 D](#fig1){ref-type="fig"}). Thus, loss of FOXO1 had no effect on the overall proliferation of virus-specific CD8^+^ T cells in response to LCMV infection.

![**Kinetics of CD8^+^ T cell expansion in response to LCMV-Arm infection.** A 1:1 mix of 10^4^ CD45.1^+^/2^+^ WT (*Foxo1*^f/f^GZMBCre^−^) and CD45.2^+^ *Foxo1*^−/−^ (Foxo1^f/f^GZMBCre^+^) P14 cells were transferred to CD45.1^+^ WT host mice. Mice were then infected with LCMV-Arm, and lymphoid and nonlymphoid organs were harvested and analyzed at day 7, 12, and 19 after infection. (A) WT and *Foxo1*^−/−^ P14 cells were identified in the spleen by their expression of CD45.1, CD45.2, CD8, and Vα2 and total numbers of P14 cells were determined. DPI, days post infection. (B) Ki67 staining of spleen cells from WT and *Foxo1*^−/−^ P14 cells at different time points. (C) Expression of KLRG1 and CD62L on WT and *Foxo1*^−/−^ P14 cells isolated from the spleen. (D) Total numbers of WT and *Foxo1*^−/−^ P14 cells in the indicated organs. (E) Expression of KLRG1 and FOXO1 on WT and *Foxo1*^−/−^ P14 cells isolated from the spleen. Data representative of 1 out of 3 independent experiments each, with *n* = 3,4.](JEM_20130392_Fig1){#fig1}

FOXO transcription factors are subject to complex post-translational regulation that includes nuclear egress and cytoplasmic localization followed by 14--3-3-mediated degradation. As such, we sought to determine how the amounts of FOXO1 might change during the course of CD8^+^ T cell expansion and contraction. The results showed there was heterogeneous FOXO1 expression that was inversely correlated with KLRG1 expression ([Fig. 1 E](#fig1){ref-type="fig"}, WT). We also note that FOXO1 expression was not detected in the GZMBCre^+^ T cells. These results are consistent with the possibility that FOXO1 is active in the precursors to memory cells, and plays less of a role in KLRG1^hi^ cells. To address this issue, we focused our analysis on memory CD8^+^ T cell differentiation with or without the deletion of *Foxo1*.

KLRG1^lo^ CD8^+^ memory-precursor T cells display an enhanced effector phenotype
--------------------------------------------------------------------------------

After the peak expansion of CD8^+^ T cells in response to virus infection, effector cells selectively die, but the surviving effector cells and memory-precursor cells become quiescent, and those within the secondary lymphoid organs eventually extinguish the expression of cytotoxic effector molecules such as GZMB ([@bib26]). To examine how the deletion of *Foxo1* affected the resolution of the response, we examined CD8^+^ T cells for the expression of molecules that play a role in effector function. Although the percentage of GZMB^+^ cells among WT and *Foxo1*^−/−^ P14 cells was similar at the peak of the response ([Fig. 2 A](#fig2){ref-type="fig"}, top left), the mean fluorescence intensity (MFI) in *Foxo1*^−/−^ P14 cells was higher ([Fig. 2 A](#fig2){ref-type="fig"}, top right). In addition, WT P14 cells rapidly lost GZMB during the contraction phase (d12-19), whereas *Foxo1*^−/−^ P14 cells retained GZMB in reduced, though substantial amounts. In fact, the KLRG1^lo^ cells increased GZMB expression at d19 against a constant expression within the KLRG1^hi^ population. Similarly, the KLRG1^lo^ *Foxo1*^−/−^ T cells regained expression of CD69 during the contraction phase ([Fig. 2 A](#fig2){ref-type="fig"}, bottom), and comparable results for the expression of GZMB and CD69 were found for liver T cells (not depicted). These data suggest that in the absence of FOXO1, CD8^+^ T cells fail in their transition from effector to memory cells, showing a sustained effector phenotype. How the CD8^+^ T cells reexpress effector molecules in the absence of antigen is unclear. In accord with the enhanced and extended effector function, there was a greater number of *Foxo1*^−/−^ multicytokine-producing (TNF and IFN-γ) effector T cells compared with WT ([Fig. 2 B](#fig2){ref-type="fig"}). To ensure that *Foxo1*^−/−^ T cells were functional, we infected WT (*Foxo1*^f/f^GZMBCre^−^) and *Foxo1*^−/−^ (*Foxo1*^f/f^GZMBCre^+^) mice and found no detectable LCM virus by day 7 (unpublished data).

![**Phenotype of virus-specific CD8^+^ T cells.** A 1:1 mix of 10^4^ CD45.1^+^/2^+^ WT (*Foxo1*^f/f^GZMBCre^−^) and CD45.2^+^ *Foxo1*^−/−^ (*Foxo1*^f/f^GZMBCre^+^) P14 cells were transferred to CD45.1^+^ WT host mice. Mice were then infected with LCMV-Arm, and spleen cells were harvested and analyzed at different time points. (A) The expression of KLRG1, GZMB, and CD69 was determined in WT and *Foxo1*^−/−^ P14 cells at different time points (left), and the amount of GZMB (MFI) and percentage of CD69 are depicted (right). Data are representative of 3 independent experiments, with *n* = 3--4. (B) At day 7 after infection, spleen cells were stimulated with PMA and ionomycin and the frequency of IFN-γ-- and TNF-producing cells was determined. Data are representative of 2 independent experiments each, with *n* = 4.](JEM_20130392_Fig2){#fig2}

At the peak of the expansion phase, T cell diversity is evident based on the differential expression of several diverse cell surface receptors and transcription factors. For example, the KLRG1^hi^CD127^lo^ population is enriched for committed effector cells, whereas the KLRG1^lo^CD127^hi^ population is enriched for the precursors of memory T cells ([@bib24]). A complication in the present analysis is that FOXO1 directly controls the expression of CD127 at least in naive and acutely activated T cells ([@bib29]), and as such may not accurately reflect the state of CD8^+^ T cell differentiation. This is depicted in [Fig. 3 A](#fig3){ref-type="fig"}, at 7 and 12 d, where an emerging CD127^+^ population is visible in the WT but not the *Foxo1^−/−^*. However, we note that by 19 d, CD127 expression has been reestablished on a proportion of the KLRG1^lo^ cells, and this suggests that at least a subset of activated T cells can express CD127 in the absence of FOXO1.

![**Enhanced effector phenotype in the absence of FOXO1.** A 1:1 mix of 1 × 10^4^ CD45.1^+^/2^+^ WT (*Foxo1*^f/f^GZMBCre^−^) and CD45.2^+^ *Foxo1*^−/−^ (*Foxo1*^f/f^GZMBCre^+^) P14 cells were transferred to CD45.1^+^ WT host mice. Mice were then infected with LCMV-Arm, and spleen cells were harvested and analyzed at different time points. (A--E) WT, open bars; *Foxo1*^−/−^, filled bars. (A) The expression of KLRG1 and CD127 was determined in WT and *Foxo1*^−/−^ P14 cells, and the percentage of CD127^+^ cells is depicted (bottom). (B) The expression of KLRG1 and EOMES was determined in WT and *Foxo1*^−/−^ P14 cells, and the percentage of EOMES^+^ cells is depicted (bottom). (C and D) WT and *Foxo1*^−/−^ P14 cells were analyzed for their expression of TCF7 (C) and TBX21 (D), and the amount of both are presented as mean fluorescence intensity (MFI, right). (E) The expression of KLRG1 and CXCR3 was determined in WT and *Foxo1*^−/−^ P14 cells (left), and the percentage of CXCR3^+^ cells depicted (right). Data are representative of 3 independent experiments each, with *n* = 3--4.](JEM_20130392_Fig3){#fig3}

The T-box transcription factors EOMES (eomesodermin) and TBX21 (T-bet) are required for the formation and function of effector and memory CD8^+^ T cells ([@bib25]). TBX21 is required for the formation of KLRG1^hi^ effector cells, and its overexpression skews the population toward terminal effector cell differentiation. In contrast, EOMES is required for T cells to survive in the long term as memory cells expressing IL2Rβ (CD122; [@bib21]; [@bib5]). An examination of co-transferred WT and *Foxo1*^−/−^ P14 cells showed that within the WT T cell population there was a remaining KLRG1^lo^EOMES^hi^ population at 19 d after infection that was largely missing in the *Foxo1*^−/−^ P14 cells ([Fig. 3 B](#fig3){ref-type="fig"}). This correlates with the absence of the high-mobility group protein, TCF7, a Wnt-activated transcription factor shown to be important for *Eomes* expression and maintenance of CD8^+^ memory T cells ([@bib67]; [Fig. 3 C](#fig3){ref-type="fig"}). Thus, there was a substantial deficit in the expression of two transcription factors shown to be required for the maintenance and function of CD8^+^ memory T cells.

Collectively, these results demonstrate an important role for FOXO1 in regulating essential characteristics associated with the lineage of precursor cells destined to become self-renewing, long-lived memory T cells. A recent study showed that IL-12 promotes *Tbx21* expression by inactivating FOXO1, and *Tbx21* expression can be inhibited indirectly by FOXO1 overexpression ([@bib48]). Furthermore, FOXO1 appears to directly target *Eomes*, and thus constitutes a second pathway that converges on *Eomes* expression to promote a memory cell phenotype ([@bib48]). In line with these results, *Foxo1*^−/−^ P14 cells displayed higher TBX21 expression compared with WT P14 cells ([Fig. 3 D](#fig3){ref-type="fig"}), and this correlated with lower levels of EOMES ([Fig. 3 B](#fig3){ref-type="fig"}), supporting a critical role for FOXO1 in regulating both *Tbx21* and *Eomes* expression.

Finally, CXCR3 is up-regulated on CTLs after activation and is thought to facilitate colocalization of T cells with viral antigens in the spleen. Whereas KLRG1^hi^ P14 cells were shown to exhibit a heterogeneous expression pattern, KLRG1^lo^ T cells remained uniformly CXCR3^hi^ throughout a viral response ([@bib20]). This was seen for both WT and *Foxo1*^−/−^ P14 cells ([Fig. 3 E](#fig3){ref-type="fig"}), suggesting that *Foxo1*^−/−^ CD8^+^ T cells have equal access to antigen, and that this aspect of CTL differentiation appears to be unaffected by *Foxo1* deletion.

Foxo1^−/−^ CD8^+^ T cells fail to up-regulate memory-associated signature genes
-------------------------------------------------------------------------------

To obtain an unbiased analysis of genes differentially expressed in antigen-specific *Foxo1^−/−^* CD8^+^ T cells responding to infection, we performed microarray analysis on KLRG1^lo^ and KLRG1^hi^ FACS-sorted, congenically marked WT and *Foxo1*^−/−^ P14 cells 8 d after infection with LCMV-Arm ([Fig. 4](#fig4){ref-type="fig"}). For this experiment, we performed gene deletion in *Rosa26*^Cre-ERT2^ *Foxo1*^f/f^ (*Foxo1*^−/−^) P14 mice just before adoptive transfer ([@bib29]). A virtually complete deletion of *Foxo1* was obtained before adoptive transfer and maintained throughout the duration of the experiment (unpublished data). We used a replicate mixed transfer experimental design to sort *Foxo1*^f/f^ (WT) and *Foxo1*^−/−^ P14 cells of the same TCR specificity from the same infected animals, thus controlling for cytokine environment and antigen load on CTL gene expression ([Fig. 4 A](#fig4){ref-type="fig"}). We compared the gene expression profile between WT versus *Foxo1*^−/−^ P14 CD8^+^ T cells in KLRG1^lo^ ([Fig. 4 B](#fig4){ref-type="fig"}) and KLRG1^hi^ ([Fig. 4 C](#fig4){ref-type="fig"}) sorted cells. The data showed that FOXO1 regulates gene expression in both populations. We then focused our analysis on sorted KLRG1^lo^ T cells known to seed the memory population and display abundant differences in both effector molecules and key transcription factors when compared with KLRG1^hi^ T cells ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, respectively; [@bib25]). We identified genes passing a twofold up or down cut-off in KLRG1^lo^ cells, identifying 27 genes down and 59 genes up in WT relative to *Foxo1*^−/−^ P14 CD8^+^ T cells ([Fig. 4, B and D](#fig4){ref-type="fig"}). As expected, and as a positive control for our analysis, we observed decreased abundance of mRNAs of known FOXO1 targets in *Foxo1*^−/−^ P14 CD8^+^ T cells: *Sell* (3.9 fold); *Ctla4* (3.8 fold); *Il7r* (10.1 fold); and *Foxo1* itself (2.5 fold; [Fig. 4 D](#fig4){ref-type="fig"}). We grouped the twofold list of regulated genes into naive/memory, effector, or no pattern based on their expression during the CD8^+^ T cell response to infection as reported by the Immgen project ([@bib7]). Interestingly, *Foxo1*^−/−^ P14 CD8^+^ T cells were enriched for genes associated with effector T cells, whereas WT P14 CD8^+^ T cells genes were enriched for genes associated with T cell naive/memory ([Fig. 4 D](#fig4){ref-type="fig"}, pie charts).

![**Deletion of *Foxo1* prevents the development of a memory program of gene expression.** A 1:1 mix of 10^4^ WT (*Foxo1*^f/f^ *Rosa26*) and *Foxo1*^−/−^ (*Foxo1*^f/f^ *Rosa26*^Cre-ERT2^) P14 cells were prepared from tamoxifen-treated mice and transferred to CD45.1^+^ WT host mice. Microarray gene-expression analysis was performed by sorting WT and *Foxo1*^−/−^ KLRG1^lo^ P14 cells 8 d after infection with LCMV-Arm. (A) Experimental scheme for mixed transfer and FACS of WT and *Foxo1*^−/−^ P14 T cells on day 8 of LCMV-Armstrong infection. The four double-sorted populations were analyzed on the same microarray chip. (B) KLRG1^lo^ WT versus *Foxo1*^−/−^ reveals 59 genes up and 27 genes down with a twofold cutoff. (C) KLRG1^hi^ WT versus *Foxo1*^−/−^ reveals 47 genes up and 45 genes down with a twofold cutoff. (D) Identification of genes KLRG1^lo^ WT / *Foxo1*^−/−^ with a twofold cutoff. Pie charts indicate portion of genes with an expression pattern tied to naive/memory (blue), effector (red), or no pattern (gray). Asterisk indicates expression was verified by flow cytometry. (E) Classification of a subset of the genes in (D) by function. (F) Genes differentially regulated in WT KLRG1^lo^ versus WT KLRG1^hi^, were overlaid with genes from KLRG1^lo^ WT versus KLRG1^lo^ *Foxo1*^−/−^ CD8^+^ T cells, showing nearly a 90% concordance of transcripts. (G) Naive CD4^+^ ChIP-Seq data showing several FOXO1 binding sites proximal to and within *Tcf7*. Data were analyzed from T reg cells and two different datasets analyzing naive CD4 T cells. Peaks are labeled as putative: intergenic enhancer (E), promoter (P), and intronic enhancers 1, 2, and 3 (I1, I2, I3). Peak sequences are listed in [Table I](#tbl1){ref-type="table"}. (H) Transcription factors known to play a role in the formation of memory cells, summarizing data presented in D with the addition of other transcription factors differentially regulated in WT vs. *Foxo1*^−/−^ P14 cells. Data are from 1 experiment with *n* = 3.](JEM_20130392R_Fig4){#fig4}

Although 8 d after infection has been found to be the peak of cytotoxic T cell expansion, virus has been cleared by this point, and subsets of CTL can already be identified as terminally differentiated effector cells or memory cell precursors. Memory precursors are associated with expression of *Id3*, *Eomes*, and *Tcf7*, whereas terminally differentiated effectors are associated with expression of *Prdm1* (BLIMP1), *Id2*, and elevated *Tbx21* ([@bib25]). As shown, these signature transcription factors are differentially regulated in KLRG1^lo^ *Foxo1*^−/−^ versus WT P14 cells ([Fig. 4 E](#fig4){ref-type="fig"}, left); furthermore, these results are consistent with aforementioned results ([Fig. 3, B--D](#fig3){ref-type="fig"}) showing that TCF7 and EOMES were markedly reduced in *Foxo1*^−/−^ T cells, whereas *Tbx21* was increased. In addition, CTLs exert their effector function through the granule exocytosis pathway, FAS, and cytokine production. We found elevated granzymes, perforin, *Fas*, and *Ifng* in KLRG1^lo^ *Foxo1*^−/−^ P14 cells. We further analyzed KLRG1^lo^ cells for activation and trafficking molecules ([Fig. 4 E](#fig4){ref-type="fig"}, right). Altogether, these data show a bias for *Foxo1*^−/−^ CD8^+^ T cells toward terminal differentiation, increased effector function, and altered trafficking/activation ([Fig. 4 E](#fig4){ref-type="fig"}, middle and right).

From our sorted cells, we made an expression list of genes up or down in WT KLRG1^lo^ versus WT KLRG1^hi^. This established a list of genes expressed at higher levels in terminal-effector cells relative to those T cells with increased memory potential. When we overlaid the genes up or down 1.5-fold from this list into a volcano plot of WT versus *Foxo1*^−/−^ KLRG1^lo^ CD8^+^ T cells, there was an ∼90% concordance of transcripts; genes associated with terminal effector cells were increased in *Foxo1*^−/−^ T cells, whereas genes associated with memory-precursor cells were increased in WT ([Fig. 4 F](#fig4){ref-type="fig"}). Specifically, the results show that *Foxo1*^−/−^ KLRG1^lo^ cells are enriched for terminally differentiated transcripts (87% of KLRG1^hi^-biased transcripts are higher in KLRG1^lo^ *Foxo1*^−/−^ versus KLRG1^lo^ WT), whereas WT KLRG1^lo^ cells are enriched for memory transcripts (88% of the KLRG1^lo^-biased transcripts are up in WT KLRG1^lo^ versus *Foxo1*^−/−^ KLRG1^lo^). A trivial explanation for this analysis would be that there was a bias for KLRG1^hi^ cell differentiation caused by the absence of FOXO1, and the microarray data simply reflects this while not revealing a direct role for *Foxo1* in driving memory cell differentiation. However, at the peak of the response there are approximately equivalent proportions of KLRG1^hi^ and KLRG1^lo^ cells in WT and Foxo1^−/−^ T cells, and yet TCF7, EOMES, TBX21, and GZMB on KLRG1^lo^ cells are differentially expressed within these populations throughout infection ([Figs. 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}). We infer that the effect is not simply a population bias but an intrinsic FOXO1-dependent effect on key memory and effector molecules. These results suggest a failure of *Foxo1*^−/−^ CD8^+^ T cells at the peak of the response to differentiate into memory-precursor cells.

The fact that so many genes associated with the memory state are of decreased abundance in *Foxo1*^−/−^ T cells suggests two nonmutually exclusive possibilities. One, FOXO1 is essential to terminate the effector state allowing genes required for differentiated memory cells to be expressed under the control of other factors. Two, FOXO1 is essential for driving the memory program through direct induction of known targets *Sell*, *Il7r*, and of master transcription factors of memory such as *Tcf7* and *Eomes* ([@bib47]; [@bib67]). *Tcf7* is expressed in both CD4^+^ and CD8^+^ T cells from early thymic developmental stages and in peripheral cells, it is notably absent in effector cells and then once again expressed in high amounts in memory T cells ([@bib63]; [@bib7]).

In support of a direct role for FOXO1 in memory cell formation, we have determined, using a chromatin immunoprecipitation sequencing (ChIP-Seq) approach, that FOXO1 binds directly to multiple sites close to, and within the *Tcf7* gene in naive CD4^+^ T cells, and these binding sites were also found in two other T cell-specific ChIP-Seq datasets ([Fig. 4 G](#fig4){ref-type="fig"}). Five of the peaks were tentatively labeled as E (intergenic enhancer), P (promoter), I1 (intronic enhancer-1), I2 (intronic enhancer-2), and I3 (intronic enhancer-3). For each of these elements, we list the nucleotide sequences corresponding to each ChIP-Seq peak ([Table I](#tbl1){ref-type="table"}). As shown, each has one or more tandem consensus forkhead binding sequences at or surrounding the peak, and this is consistent with specific FOXO1 binding. In addition, we show the H3K4me3 histone marks at the transcription start site indicative of an open locus ([@bib45]). This apparently direct regulation of *Tcf7* suggests that memory cell differentiation after TCR and cytokine stimulation requires FOXO1 nuclear localization.

###### 

Nucleotide sequences found at FOXO1-binding peaks within the *Tcf7* gene

  Element[a](#tblfn1){ref-type="table-fn"}   Peak sequences
  ------------------------------------------ ---------------------------
  E                                          5′-TATCT**TGTTT**TGCTC-3′
  P                                          5′-GGAGT**AAACA**GACCC-3′
  I1                                         5′-ACTGT**TGTTT**CCTGC-3′
                                             5′-TGTAC**AAACA**AGGCT-3′
                                             5′-GGAGG**AAACA**GGTGT-3′
  l2                                         5′-CAGGG**TGTTT**GTAGT-3′
                                             5′-TCTAA**AAACA**TCCTG-3′
                                             5′-AAGGA**AAACA**CAAGC-3′
  l3                                         5′-GACTG**TGTTT**ATTTT-3′
                                             5′-CTCTG**AAACA**GAGAC-3′

Sequences in bold correspond to a forkhead consensus site.

See [Fig. 4 G](#fig4){ref-type="fig"}.

Finally, for clarity, we summarized the data focusing on transcription factors differentially regulated in WT versus *Foxo1*^−/−^ P14 T cells ([Fig. 4 H](#fig4){ref-type="fig"}). This list includes other transcription factor genes known to play a role in the formation of memory, such as the *Tcf7*-related *Lef1* ([@bib66]). It also may point to a role for FOXO1-regulated transcription factors and DNA binding proteins as of yet not recognized as being involved in CD8^+^ T cell memory formation.

Collectively, these analyses suggest a basic and essential role for FOXO1 in programming fundamental aspects of the memory state in CD8^+^ T cells after response to infection in vivo. We therefore tested whether *Foxo1*^−/−^ T cells can expand in response to a secondary antigenic challenge as a measure of the requirement for *Foxo1* in an immune recall response.

Foxo1^−/−^ CD8^+^ T cells fail to make a memory response
--------------------------------------------------------

The data presented demonstrate that, in the absence of FOXO1, virus-specific CD8^+^ T cells display a prolonged effector phenotype and fail to up-regulate a multitude of key memory-associated genes. To better understand the role of FOXO1 in CD8^+^ T cell differentiation after viral infection, we characterized *Foxo1*^−/−^ P14 spleen cells from LCMV-Arm infected mice at later time points (35 d after infection). As seen for early time points ([Fig. 1 A](#fig1){ref-type="fig"}), the numbers of P14 cells were comparable between WT and *Foxo1*^−/−^ P14 cells ([Fig. 5 A](#fig5){ref-type="fig"}). Even at this later time, *Foxo1*^−/−^ P14 cells exhibit an enhanced effector-like phenotype ([Fig. 5 B](#fig5){ref-type="fig"}) characterized by low expression of the memory-associated marker CD127, and high expression of CD69 and GZMB. As shown for early time points ([Fig. 2 A](#fig2){ref-type="fig"}; and [Fig. 3, A and B](#fig3){ref-type="fig"}), this phenotype was only observed in KLRG1^lo^ memory-like cells ([Fig. 5, B and C](#fig5){ref-type="fig"}). This KLRG1^lo^ population also expressed high amounts of the high-affinity IL-2 receptor CD25 and low levels of the IL-2 receptor β-chain CD122 ([Fig. 5 C](#fig5){ref-type="fig"}), consistent with the microarray data ([Fig. 4 E](#fig4){ref-type="fig"}, right). Early in infection, high CD25 expression was shown to promote terminal-effector CD8^+^ T cell differentiation in vivo ([@bib27]), while high CD122 expression is associated with CD8^+^ memory T cells ([@bib21]). This supports the concept that FOXO1 is essential for the transition from effector to long-lived memory CD8^+^ T cells. In addition, the expression of memory-related transcription factors EOMES and TCF7 was still low, whereas the expression of TBX21 was higher in KLRG1^lo^ *Foxo1*^−/−^ P14 cells compared with WT at this late time-point ([Fig. 5 D](#fig5){ref-type="fig"}). These phenotypic changes are consistent with an extended effector-like phenotype in *Foxo1*^−/−^ T cells ([Fig. 5 B](#fig5){ref-type="fig"}).

![***Foxo1*^−/−^ CD8^+^ T cells fail to expand upon secondary viral challenge.** (A--E) WT, open squares; *Foxo1*^−/−^ filled squares. A 1:1 mix of 10^4^ CD45.1^+^/2^+^ WT (*Foxo1*^f/f^GZMBCre^−^) and CD45.2/2^+^ *Foxo1*^−/−^ (*Foxo1*^f/f^GZMBCre^+^) P14 cells were prepared and transferred to CD45.1^+^ WT host mice. Mice were then infected with LCMV-Arm, and spleen cells were analyzed 35 d after infection. (A) Number of cells recovered per spleen at day 35. (B) WT and *Foxo1*^−/−^ P14 cells were analyzed by their expression of KLRG1 and CD127, CD69, and GZMB (top), and the MFI of these molecules was quantified on the KLRG1^lo^ population (bottom). (C) Expression of CD25 and CD122 on KLRG1^lo^ P14 cells. (D) WT and *Foxo1*^−/−^ P14 cells were analyzed for expression of transcription factors important for CD8^+^ memory and effector T cells, and the amount of protein expressed on the KLRG1^lo^ population graphed as MFI. (E) P14 (CD8^+^Vα2^+^) WT (CD45.1^+^/2^+^) and *Foxo1*^−/−^ (CD45.1^+^) cells from hosts 35 d after LCMV-Arm infection were sorted and transferred at a 1:1 ratio into naive WT mice. Mice were then infected with LCMV-Arm and the expansion of WT and *Foxo1*^−/−^ P14 cells determined at d 5 after infection (top right). The phenotype of P14 T cells 5 d after secondary challenge (bottom). Data are representative of 2 independent experiments for a total *n* = 11.](JEM_20130392R_Fig5){#fig5}

Finally, we tested the ability of these cells to respond to a second challenge with LCMV-Arm. To do this, WT and *Foxo1*^−/−^ P14 cells were sorted from mixed adoptively transferred mice at 35 d after infection and transferred as a 1:1 mixture into naive recipients. These mice were challenged with LCMV-Arm and analyzed for T cell expansion 5 d post-infection ([Fig. 5 E](#fig5){ref-type="fig"}). The results showed that in the absence of FOXO1, CD8^+^ T cells failed to accumulate, and were at a 45-fold disadvantage with respect to the WT CD8^+^ T cells. Of note, the phenotype of the cells post-challenge ([Fig. 5 E](#fig5){ref-type="fig"}) was similar to the one found at the peak of the response during the primary infection ([Figs. 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), with higher expression of GZMB in *Foxo1*^−/−^ P14 cells compared with WT P14 cells. Collectively, the results of the experiments described demonstrate an intrinsic role for FOXO1 in regulating the transition from effector cells to long-lived memory cells capable of reactivation.

DISCUSSION
==========

Infection by an intracellular pathogen almost invariably results in the expansion of antigen-specific CD8^+^ T cells that participate in killing the pathogen-infected cells. These T cells exhibit characteristics of terminal differentiation in that they have a finite life span and they maintain a highly differentiated program of gene expression associated with cytotoxicity and inflammation. Although competing models of CTL memory exist, available evidence favors the concept that memory-precursor cells differentiate from a subset of this effector population, ultimately becoming a cell-type perhaps like no other in the immune system. These memory T cells are self-renewing, with a population turnover of 2--3 mo, and their progeny can be shown to persist for the life of the individual ([@bib42]; [@bib10]). Yet, they are poised to respond to a reinfection by rapid growth, progression through the cell cycle, and expression of a cytotoxic, proinflammatory program of gene expression ([@bib57]; [@bib36]; [@bib64]).

The control of the effector versus memory-precursor lineage decision has been illuminated over the past decade, including a role for stimulatory and inflammatory cytokines as well as a description of several transcription factors necessary for the distinct programs of gene expression ([@bib49]; [@bib7]). In this study, we describe experiments that demonstrate a high order control over this fate decision mediated by the forkhead transcription factor, FOXO1. With the deletion of *Foxo1*, CD8^+^ T cells fail to acquire the characteristics of memory-precursor cells 7 d post-infection, they retain many aspects of effector T cells for an extended period, and they do not exhibit the vast expansion characteristic of a recall immune response. Given its extensive range of posttranslational modifications ([@bib18]), we infer that the lineage decision to acquire characteristics of effector vs. memory-precursor cells would appear to center, to an extent, on the integration of extrinsic signals that are manifest in the cellular localization and target specificity of FOXO1.

These results are in concert with studies showing that activation of AKT, a major pathway to FOXO inhibition, is key to the differentiation of effector cells at the expense of memory-precursory cells ([@bib17]; [@bib31]). In addition, the IL-12--mediated inactivation of FOXO1 was shown to promote TBX21--expressing effector T cells, and the rapamycin-mediated inhibition of TBX21 expression was FOXO1 dependent. Also, this same study established a role for FOXO1 in switching T cells from an effector to a memory-like phenotype through an increase in EOMES expression ([@bib48]). Here, we establish that FOXO1, in the context of rapidly expanding T cells, directly and indirectly refines a program of gene expression to produce the phenotypic characteristics of memory cells. Of particular importance may be a direct role for FOXO1 in controlling the expression of *Tcf7*, encoding a Wnt, β-catenin-regulated transcription factor. This might be viewed as contrary to studies showing that FOXO factors compete with β-catenin for TCF interactions, and thus suppress the expression of TCF target genes; however, these studies examined FOXO3 and FOXO4. We surmise that this effect may not apply to FOXO1, but rather, FOXO1 may transcriptionally promote the expression of *Tcf7* ([@bib2]; [@bib19]). In this regard, the present results closely parallel those analyzing *Tcf7* mutant T cells in that such T cells maintain expression of GZMB, and exhibit reduced expression of EOMES, CD62L, CCR7, and IL2β ([@bib67]). Our conclusion is that FOXO1 is required for the expression of *Tcf7* as part of an extended program of gene expression that gives rise to memory T cells.

FOXO1 has been found to regulate pluripotency and self-renewal in several contexts. In embryonic stem cells (ES cells) in mouse and human beings, it does so by direct control of *Oct4* and *Sox2*---encoding two of the factors necessary to maintain pluripotency in ES cells or induce pluripotency in differentiated cell types ([@bib65]). It is necessary for the maintenance of tumor stem cells in acute myelogenous leukemia (AML) cells, which explains the paradoxical finding that AKT activation or the inactivation of multiple *Foxo* genes can inhibit tumorigenicity in many examples of AML ([@bib55]). In addition, FOXO factors are essential for the maintenance of hematopoietic stem cells, although largely through the detoxification of reactive oxygen species ([@bib58]). Although we might be tempted to draw parallels between the self-renewal capacity of stem cells and memory T cells, we note that FOXO transcription factors have also been shown to control acne ([@bib35]), bone homeostasis ([@bib1]), liver metabolism ([@bib33]), muscle mass ([@bib15]), and the trade-off between aging and cancer ([@bib32]). In fact, there may be few physiological processes that are not guided, at least in part, by FOXO transcription factors. Perhaps what all these processes have in common is a requirement for integrating characteristics defining the physiological state of the organism to effect an adaptively advantageous program of gene expression different for each and every tissue. A corollary to this thesis is that gene expression is not determined by any one transcription factor; rather, a transcription factor exerts activity in a highly context-dependent manner ([@bib6]).

These results imply that AKT-mediated inhibition of FOXO1 ensures the memory program is not prematurely engaged, as early in the response, the cytokine or TCR-driven cytoplasmic sequestration of FOXO1 may promote high TBX21 and an effector phenotype so long as antigen is present. How this pathway plays into T cell exhaustion in chronic infection or continued formation of memory T cells in viral latency will be a topic of future studies. An implication is that the magnitude and effectiveness of a recall immune response may depend on the physiological state of the individual, where high levels of growth factors or superabundant nutrients may well blunt the formation or function of memory T cells. In addition, the role of memory T cells in persistent or latent viral infections is only beginning to be understood ([@bib62]), and the course of such an infection could be readily affected by the activity of FOXO1 in antigen-specific T cells. The delicate balance between latency and recrudescence may be controlled in part through inactivation of FOXO caused by physiological stress.

MATERIALS AND METHODS
=====================

### Mice and tamoxifen treatment.

C57BL/6 CD45.1^+^ mice were maintained in pathogen-free conditions. *Rosa26*^Cre-ERT2^ mice were provided by T. Ludwig (The Ohio State University, Columbus, OH; [@bib16]). *Foxo1*^f/f^ and Tg(GZMB-cre)1Jcb/J (GZMBCre) mice have been previously described ([@bib22]; [@bib40]). *Foxo1*^f/f^ mice (backcrossed to C57BL/6, *n* \> 12) were crossed to GZMBCre or *Rosa26*^Cre-ERT2^ mice. In addition, mice were crossed with Tg(TcrLCMV)327Sdz (P14) mice to generate *Foxo1*^f/f^ GZMBCre^+^P14 or *Foxo1*^f/f^ *Rosa26*^Cre-ERT2^ P14 CD45.2^+^ mice. CD45.1^+^/2^+^ WT P14 mice were produced by a further cross with CD45.1^+^ C57BL/6 mice. *Rosa26*^Cre-ERT2^-mediated deletion of floxed alleles was induced by intraperitoneal injection of 1 mg of tamoxifen (Sigma-Aldrich) emulsified in 200 ml of sunflower seed oil (Sigma-Aldrich) every day for 5 d, followed by 5 d of rest (*ER*cre^+^, *Foxo1*^−/−^; *ER*cre^−^, WT). All procedures were approved by the Animal Care and Use Committee of the University of California, San Diego.

### Adoptive transfer and viral infection.

Spleen cells were harvested from mice as described in the previous section. P14 cells were identified as CD8^+^Vα2^+^ and numbers were adjusted to obtain a 1:1 mix of 10^4^ WT:*Foxo1*^−/−^ cells. P14 cells were transferred intravenously to 8--10-wk-old CD45.1^+^ WT host mice. Mice were then infected with 2 × 10^5^ pfu LCMV-Armstrong i.p. Virus was grown, identified, and quantified as previously described ([@bib12]).

### Flow cytometry.

Cell suspensions isolated from the indicated organs were incubated for 15 min at 4°C in PBS containing 1% FCS (Omega), 2 mM EDTA, 0.01% NaN3, and the indicated fluorochrome-conjugated antibodies. All intracellular staining was done with FoxP3 Fix/Perm (eBioscience). Antibodies against FOXO1 and TCF7 (rabbit polyclonal) were purchased from Cell Signaling Technology. Alexa Fluor 647 anti--rabbit secondary antibody and PE-conjugated anti--human Granzyme B (GZMB) antibodies were purchased from Invitrogen. The rest of the antibodies used were purchased from eBioscience or BD. Data were collected on a Fortessa (BD) and analyzed with FlowJo software (Tree Star).

### Cell sorting and microarray.

Splenocytes were harvested and the CD8^+^ fraction enriched by negative selection using biotinylated antibodies against CD4, B220, CD11c, and DX5 (all from eBioscience), followed by streptavidin microbeads using MACS system in a 4°C cold room (Miltenyi Biotec). The negative fraction was then stained with antibodies against CD45.1, CD45.2, KLRG1, CD8, and Vα2. KLRG1^lo^ donor WT (CD45.1^+^/2^+^) and *Foxo1*^−/−^ (CD45.2^+^) P14 (CD8^+^Vα2^+^) splenocytes were sorted from host mice on day 7 after LCMV Armstrong infection using a BD ARIA (BD). Total RNA was extracted from sorted cells using RNeasy Microkit (QIAGEN), and RNA was labeled with biotin with the BioArray High Yield RNA Transcript Labeling kit (Enzo Diagnostics) and purified with an RNeasy Mini kit (QIAGEN). The resulting cRNA was hybridized to GeneChip Mouse Gene 1.0 ST arrays at the UCSD VA/VMRF microarray and NGS core. The raw CEL files were obtained, and the data were normalized and analyzed with the GenePattern software suite.

### ChIP and ChIP-seq.

Methods for ChIP-Seq are described previously ([@bib34]). Sequences were mapped to the mouse genome mm9 assembly (NCBI) using the Bowtie alignment tool and unique tags were visualized by preparing custom tracks for the UCSC Genome Browser where the total number of tags was normalized to 10^7^. DNA sequence analysis was performed using HOMER. Data are have been deposited in the the Gene Expression Omnibus database under accession no. [GSE46025](GSE46025). Foxo1 binding was referenced for T reg cells ([@bib51]) and two datasets for naive CD4 T cells (Naive 1; [@bib39]; Naive2; this study). H3K4me3 histone marks were analyzed as previously described ([@bib34]).

### Statistical analysis.

Differences between datasets were analyzed by unpaired two-tailed Student's *t* test or two-way ANOVA, as indicated.
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